bristol-myers glp-1 receptor agonist products Market Overview: Agonists and the Obesity Market | Blog GLP-1 Receptor Agonist Market Size,
Description
Oral semaglutide was superior to placebo, sitagliptin, and liraglutide and similar to empagliflozin, with losses up to 4.44 kg compared with 0.53.6 kg for active-comparator arms and 0.41.4 kg compared with placebo [35,36,37,38,39,40]
Among the main obstacles are the complicated interactions between genetic and environmental variables, poor adherence to lifestyle modifications, and restricted access to therapies, especially in low- and middle-income countries
Hiramatsu, T
-Restraint: Manufacturing complexities and high cost of biosimilars
Weimers, P
